Suppr超能文献

糖尿病与心血管疾病:探索流行病学、病理生理学及治疗策略

Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies.

作者信息

Siam Nawfal Hasan, Snigdha Nayla Nuren, Tabasumma Noushin, Parvin Irin

机构信息

Department of Pharmacy, School of Pharmacy and Public Health, Independent University, Bangladesh (IUB), 1229 Dhaka, Bangladesh.

Department of Biomedical Science, School of Health and Life Sciences, Teesside University, TS1 3BX Middlesbrough, UK.

出版信息

Rev Cardiovasc Med. 2024 Dec 11;25(12):436. doi: 10.31083/j.rcm2512436. eCollection 2024 Dec.

Abstract

Diabetes mellitus (DM) affects 537 million people as of 2021, and is projected to rise to 783 million by 2045. This positions DM as the ninth leading cause of death globally. Among DM patients, cardiovascular disease (CVD) is the primary cause of morbidity and mortality. Notably, the prevalence rates of CVD is alarmingly high among diabetic individuals, particularly in North America and the Caribbean (46.0%), and Southeast Asia (42.5%). The predominant form of CVD among diabetic patients is coronary artery disease (CAD), accounting for 29.4% of cases. The pathophysiology of DM is complex, involving insulin resistance, β-cell dysfunction, and associated cardiovascular complications including diabetic cardiomyopathy (DCM) and cardiovascular autonomic neuropathy (CAN). These conditions exacerbate CVD risks underscoring the importance of managing key risk factors including hypertension, dyslipidemia, obesity, and genetic predisposition. Understanding the genetic networks and molecular processes that link diabetes and cardiovascular disease can lead to new diagnostics and therapeutic interventions. Imeglimin, a novel mitochondrial bioenergetic enhancer, represents a promising medication for diabetes with the potential to address both insulin resistance and secretion difficulties. Effective diabetes management through oral hypoglycemic agents (OHAs) can protect the cardiovascular system. Additionally, certain antihypertensive medications can significantly reduce the risk of diabetes-related CVD. Additionally, lifestyle changes, including diet and exercise are vital in managing diabesity and reducing CVD risks. These interventions, along with emerging therapeutic agents and ongoing clinical trials, offer hope for improved patient outcomes and long-term DM remission. This study highlights the urgent need for management strategies to address the overlapping epidemics of DM and CVD. By elucidating the underlying mechanisms and risk factors, this study aims to guide future perspectives and enhance understanding of the pathogenesis of CVD complications in patients with DM, thereby guiding more effective treatment strategies.

摘要

截至2021年,糖尿病(DM)影响着5.37亿人,预计到2045年将增至7.83亿人。这使糖尿病成为全球第九大主要死因。在糖尿病患者中,心血管疾病(CVD)是发病和死亡的主要原因。值得注意的是,糖尿病患者中心血管疾病的患病率高得惊人,尤其是在北美和加勒比地区(46.0%)以及东南亚(42.5%)。糖尿病患者中最主要的心血管疾病形式是冠状动脉疾病(CAD),占病例的29.4%。糖尿病的病理生理学很复杂,涉及胰岛素抵抗、β细胞功能障碍以及相关的心血管并发症,包括糖尿病性心肌病(DCM)和心血管自主神经病变(CAN)。这些情况加剧了心血管疾病风险,凸显了管理包括高血压、血脂异常、肥胖和遗传易感性等关键风险因素的重要性。了解将糖尿病与心血管疾病联系起来的基因网络和分子过程可以带来新的诊断和治疗干预措施。伊美格列明是一种新型线粒体生物能量增强剂,是一种有前景的糖尿病治疗药物,有可能解决胰岛素抵抗和分泌困难问题。通过口服降糖药(OHAs)进行有效的糖尿病管理可以保护心血管系统。此外,某些抗高血压药物可以显著降低与糖尿病相关的心血管疾病风险。此外,包括饮食和运动在内的生活方式改变对于管理糖尿病肥胖症和降低心血管疾病风险至关重要。这些干预措施,连同新出现的治疗药物和正在进行的临床试验,为改善患者预后和实现糖尿病长期缓解带来了希望。本研究强调迫切需要管理策略来应对糖尿病和心血管疾病的重叠流行。通过阐明潜在机制和风险因素,本研究旨在指导未来的研究方向,增进对糖尿病患者心血管疾病并发症发病机制的理解,从而指导更有效的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/490f/11683709/c3fc6c54f1ab/2153-8174-25-12-436-g1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验